# Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

> **NCT07742332** · PHASE2 · RECRUITING · sponsor: **Peng Zhang** · enrollment: 160 (estimated)

## Conditions studied

- EGFR
- NSCLC (Non-small Cell Lung Cancer)
- Locally Advanced Non-Small Cell Lung Cancer
- Radiotherapy
- Chemotherapy

## Interventions

- **DRUG:** Fumetinib combined platinum-based double chemotherapy
- **COMBINATION_PRODUCT:** Concurrent Radiochemotherapy

## Key facts

- **NCT ID:** NCT07742332
- **Lead sponsor:** Peng Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2027-11-25
- **Final completion:** 2032-11-25
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07742332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07742332, "Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07742332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*